Pacira BioSciences Defends Strategy & Performance Amidst Proxy Battle, Reports Strong Q1 2026 Growth
Summary
Pacira BioSciences issued additional proxy materials, reiterating its confidence in current management and strategy while reporting strong Q1 2026 revenue growth for its products, as it continues to defend against an activist proxy contest.
Key Events
-
Proxy Battle Update
Pacira BioSciences is urging stockholders to vote 'FOR' its three highly qualified board nominees (Christopher Christie, Samit Hirawat, MD, and Thomas Wiggans) on the BLUE proxy card, countering activist investor DOMA Perpetual Capital Management LLC.
-
Strong Q1 2026 Revenue Growth
The company reported Q1 2026 revenues of $143.3 million for EXPAREL (up ~5% y/y), $26.8 million for ZILRETTA (up ~15% y/y), and $6.2 million for iovera° (up ~21% y/y), demonstrating continued product momentum.
-
Defense of 5x30 Strategy and 2025 Performance
Pacira highlighted its '5x30 strategy' for value creation, noting a 31% stock increase since its launch and strong 2025 performance with record total revenues of $726.4 million and GAAP net income of $7.0 million.
-
Intellectual Property Protection
The company emphasized a favorable EXPAREL settlement in 2025, providing exclusivity into 2030 and a gradual transition through 2039, alongside an expanded patent estate extending into the mid-2040s.
Analysis
This filing is additional definitive proxy material from Pacira BioSciences, urging shareholders to vote for its board nominees in an ongoing proxy contest with activist investor DOMA Perpetual Capital Management LLC. The company highlights its '5x30 strategy' and strong financial performance, including new Q1 2026 revenue figures for its key products (EXPAREL, ZILRETTA, iovera°) which show positive year-over-year growth. This communication is critical as it represents the company's continued defense against the activist investor, providing updated performance metrics to support its current management and strategic direction ahead of the June 9, 2026 Annual Meeting.
At the time of this filing, PCRX was trading at $24.04 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $945.6M. The 52-week trading range was $18.80 to $27.64. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.